Q-omics provides the consensus-scored GRAPL profile across patient tissues and cancer cell-line models. GRAPL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRAPL is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, GRAPL RNA expression shows 11,945 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, UCEC, and TGCT as cancer lineages where GRAPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAPL survival associations across molecular data types. GRAPL RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAPL RNA expression–survival associations across cancer types. High GRAPL expression shows unfavorable associations in KIRP and LUSC, but favorable associations in KIRC, DLBC, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRAPL RNA expression.
This table summarizes GRAPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for GRAPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAPL shows lower tumor expression in UCEC, LUSC, LUAD, KIRP and BRCA and higher tumor expression in KIRC. The UCEC box plot shows higher GRAPL RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p = .002).
This table shows molecular features associated with GRAPL in patient tissues and cancer cell lines. In patient samples, GRAPL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRAPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
